Eicosapentaenoic and docosahexaenoic acid-enriched high fat diet delays the development of fatty liver in mice

Lipids Health Dis. 2015 Jul 22:14:74. doi: 10.1186/s12944-015-0072-8.

Abstract

Background: Low hepatic content of n-3 PUFA has been associated with NAFLD in humans. Whether this is associated with reduced dietary intake or increased turnover of these FA is not clear. We have here investigated the effects of dietary fat quality on hepatic lipid storage and transcriptomics over time.

Aim: To investigate the effects of quality of fat in a high fat diet (HFD) over time on hepatic lipid storage and liver transcriptomics.

Methods and results: Male C57BL/6J mice were fed control, HFD-eicosapentaenoic acid (EPA)/ docosahexaenoic acid (DHA) or HFD-corn oil diet for 8 or 12 weeks. Body weight, body composition, plasma and hepatic triglyceride contents were measured. Hepatic transcriptomes were analysed by microarray followed by gene-set enrichment analyses. At 8 weeks, the HFD-corn oil mice had higher body weight and adipose depot mass than the HFD-EPA/DHA but there were no differences at 12 weeks. Hepatic triglyceride content was lower in HFD-EPA/DHA fed compared with the HFD-corn oil fed mice at both time-points. Enrichment analyses of the hepatic transcriptomes showed that lipid/fatty acid biosynthesis; transport and homeostasis were lower in the HFD-EPA/DHA fed compared with the HFD-corn oil fed mice. Genes encoding proteins associated to cytoplasmic lipid droplets were expressed at higher levels in livers from the HFD-corn oil compared to HFD-EPA/DHA mice.

Conclusions: Dietary EPA and DHA counteracted development of HFD-induced fatty liver. The liver transcriptome data implicate that the quality of dietary fat could modulate Ppar-related gene expression that in turn affects hepatic lipid storage and maintenance of metabolic health.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiposity / drug effects
  • Animals
  • Diet, High-Fat*
  • Docosahexaenoic Acids / pharmacology
  • Docosahexaenoic Acids / therapeutic use*
  • Eicosapentaenoic Acid / pharmacology
  • Eicosapentaenoic Acid / therapeutic use*
  • Fatty Liver / blood
  • Fatty Liver / drug therapy*
  • Fatty Liver / pathology
  • Gene Expression Regulation / drug effects
  • Gene Ontology
  • Lipid Droplets / drug effects
  • Lipid Droplets / metabolism
  • Lipid Metabolism / drug effects
  • Lipid Metabolism / genetics
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Organ Size / drug effects
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Time Factors
  • Triglycerides / blood
  • Weight Gain / drug effects

Substances

  • Triglycerides
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid